Cargando…

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

An estimated 10 million people developed tuberculosis (TB) disease in 2019 which underscores the need for a vaccine that prevents disease and reduces transmission. The aim of our current studies is to characterize and test a prophylactic tuberculosis vaccine comprised of ID93, a polyprotein fusion a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baldwin, Susan L., Reese, Valerie A., Larsen, Sasha E., Beebe, Elyse, Guderian, Jeff, Orr, Mark T., Fox, Christopher B., Reed, Steven G., Coler, Rhea N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951850/ https://www.ncbi.nlm.nih.gov/pubmed/33705411 http://dx.doi.org/10.1371/journal.pone.0247990

Ejemplares similares

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations
por: Baldwin, Susan L., et al.
Publicado: (2022)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model
por: Kwon, Kee Woong, et al.
Publicado: (2019)

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment
por: Larsen, Sasha E., et al.
Publicado: (2018)

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
por: Baldwin, Susan L., et al.
Publicado: (2018)

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
por: Choi, Yu Hwa, et al.
Publicado: (2023)

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018)

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity
por: Larsen, Sasha E., et al.
Publicado: (2022)

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
por: Larsen, Sasha E., et al.
Publicado: (2023)

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine
por: Archer, Michelle C., et al.
Publicado: (2023)

Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event
por: Berube, Bryan J., et al.
Publicado: (2022)

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
por: Larsen, Sasha E., et al.
Publicado: (2023)

Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved In Vitro Th1-Type Cytokine Recall Responses in Human Whole Blood
por: Adeagbo, Babatunde Ayodeji, et al.
Publicado: (2020)

Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models
por: Larsen, Sasha E., et al.
Publicado: (2021)

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases
por: Baldwin, Susan L., et al.
Publicado: (2019)

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
por: Fox, Christopher B., et al.
Publicado: (2012)

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

Mycobacterium abscessus: It’s Complex
por: Abdelaal, Hazem F. M., et al.
Publicado: (2022)

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach
por: Fox, Christopher B., et al.
Publicado: (2016)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
por: Pérez, O., et al.
Publicado: (2012)

Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease
por: Lee, Ju Mi, et al.
Publicado: (2022)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology
por: Orr, Mark T., et al.
Publicado: (2019)

A structure-function approach to optimizing TLR4 ligands for human vaccines
por: Carter, Darrick, et al.
Publicado: (2016)

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults
por: Sagawa, Zachary K., et al.
Publicado: (2023)

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
por: Coler, Rhea N., et al.
Publicado: (2010)

Abstract 1647: Quantification of functional antibody titers in a mouse model of SARS-CoV-2 infection
por: Hernandez, Dulce, et al.
Publicado: (2023)

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice
por: Paes, Wayne, et al.
Publicado: (2016)

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
por: Van Hoeven, Neal, et al.
Publicado: (2018)

Expression Cloning of an Immunodominant Family of Mycobacterium tuberculosis Antigens Using Human Cd4(+) T Cells
por: Alderson, Mark R., et al.
Publicado: (2000)

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach
por: Kramer, Ryan M, et al.
Publicado: (2018)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

SARS-CoV-2 infection and immune responses
por: Harne, Rakhi, et al.
Publicado: (2023)

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE
por: Coler, Rhea N, et al.
Publicado: (2015)

A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies
por: Takashima, Eizo, et al.
Publicado: (2022)

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2016)

Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity
por: Fung, HW Millie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6k45ns4dsld72im112g35usmsd